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Expanded Abstract 
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Background 
Randomized clinical trials (RCTs) that stop earlier than 
planned because of apparent benefit often receive great 
attention and affect clinical practice. Their prevalence, the 
magnitude and plausibility of their treatment effects, and the 
extent to which they report information about how 
investigators decided to stop early are, however, unknown. 
Methods 
Objective: To evaluate the epidemiology and reporting 
quality of RCTs involving interventions stopped early for 
benefit. 
Design:  Systematic review up to November 2004 of 
MEDLINE, EMBASE, Current Contents, and full-text journal 
content databases to identify RCTs stopped early for 
benefit. 
Study selection: Randomized clinical trials of any 
intervention reported as having stopped early because of 
results favoring the intervention. There were no exclusion 
criteria. 
Data extraction: Twelve reviewers working independently 
and in duplicate abstracted data on content area and type of 
intervention tested, reporting of funding, type of end point 
driving study termination, treatment effect, length of follow-
up, estimated sample size and total sample studied, role of 
a data and safety monitoring board in stopping the study, 
number of interim analyses planned and conducted, and 
existence and type of monitoring methods, statistical 
boundaries, and adjustment procedures for interim analyses 
and early stopping. 
Data synthesis: Of 143 RCTs stopped early for benefit, the 
majority (92) were published in 5 high-impact medical 
journals. Typically, these were industry-funded drug trials in 
cardiology, cancer, and human immunodeficiency 
virus/AIDS. The proportion of all RCTs published in high-
impact journals that were stopped early for benefit 
increased from 0.5% in 1990-1994 to 1.2% in 2000-2004 
(P<.001 for trend). On average, RCTs recruited 63% (SD, 
25%) of the planned sample and stopped after a median of 
13 (interquartile range [IQR], 3-25) months of follow-up, 1 
interim analysis, and when a median of 66 (IQR, 23-195) 
patients had experienced the end point driving study 
termination (event). The median risk ratio among truncated 
RCTs was 0.53 (IQR, 0.28-0.66). One hundred thirty-five 
(94%) of the 143 RCTs did not report at least 1 of the 
following: the planned sample size (n = 28), the interim 
analysis after which the trial was stopped (n = 45), whether 
a stopping rule informed the decision (n = 48), or an 
adjusted analysis accounting for interim monitoring and 
truncation (n = 129). Trials with fewer events yielded greater 
treatment effects (odds ratio, 28; 95% confidence interval, 
11-73). 
Conclusion 
RCTs stopped early for benefit are becoming more 
common, often fail to adequately report relevant information 
about the decision to stop early, and show implausibly large 
treatment effects, particularly when the number of events is 
small. These findings suggest clinicians should view the 
results of such trials with skepticism. 
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Commentary 
Randomized controlled trials (RCTs) stopped early for 
benefit are increasingly common and frequently earn 
publication in high impact journals. Such trials typically 
report impressive treatment effects and generate 
considerable enthusiasm. Yet, there may be reason to be 
cautiously skeptical when a trial is stopped early for benefit. 
In the current study, Montori and coworkers [1] 
systematically reviewed RCTs of any intervention reported 
as having been stopped early because of results favoring 
the intervention. Their review included trials with results 
published in MEDLINE, EMBASE, Current Contents, and 
full-text journal content databases up to November 2004. 
The authors identified 143 RCTs stopped early for benefit, 
the majority of which were industry-funded drug trials in 
cardiology, cancer, and AIDS. They noted that  the number 
of trials stopped early has increased significantly over the 
past 15 years and that 94% of these failed to report at least 
one of several key details about trial design or the decision 
to stop, as required by the CONSORT guidelines [2,3]. 
Montori and coworkers also found a strong inverse 
relationship between the reported event rate and estimated 
treatment effect, meaning that small trials with few events 
were likely to report large treatment effects. The median risk 
ratio (RR) of the truncated trials was an implausible 0.53. 
Comparatively, not a single study with more than 195 
outcome events generated a RR < 0.50. Because the 
decision to stop is typically driven by highly significant p-
value thresholds, trials stopped early because of apparent 
benefit frequently show large treatment effects. Ioannidis 
recently highlighted a startlingly similar association between 
small sample size and likelihood of a trial’s findings being 
challenged and refuted over time [4]. 
A timely example of a trial that could have been stopped 
early but was not is OPTIMIST (Optimized Phase 3 
Tifacogin In Multicenter International Sepsis Trial) [5]. At a 
planned interim analysis, tifacogin appeared to provide a 
clinically and statistically significant survival benefit 
compared to placebo (29.1% vs 38.9%, P=0.006). However, 
the survival difference was not large enough to activate the 
predefined stopping rule and the study continued. 
Interestingly, the benefit of tifacogin vanished as the study 
reached completion (34.2% vs 33.9%, P=0.88) (Figure). 
Despite thorough investigation of drug formulation, study 
procedures, and clerical data, the best explanation for the 
early inclination of benefit is the play of chance [6]. In other 
words, early on in the trial, the tifiacogin group was on a 
“random high”  [7,8]. 
The points raised by Montori and coworkers are notable for 
the discipline of critical care medicine; seven percent of 
reviewed articles were generated by our specialty. Four 
trials that were stopped early (perioperative beta-blockade 
[9], low tidal volume ventilation [10], recombinant human 
activated protein C [11], and tight glucose control [12]) have 
altered the landscape of critical care practice within the past 
10 years. These trials have generated more than their fair 
share of controversy, which might have been minimized if 
they had been continued to completion. 
Montori’s group draws attention to legitimate issues and 
engenders additional questions. Most importantly, should 
therapeutic trials ever be halted for benefit? The 
accompanying editorial [13] suggests that trials should only 
be stopped early for benefit when there is a highly 
significant p-value (e.g., p<0.001) and after sufficient 
outcome events have been observed. This more stringent 
approach may result in randomizing subsequent patients to 
a potentially inferior treatment, an option that seems at odds 
with safety ethics. Viewed more broadly, however, avoiding 
premature conclusions that could be both costly and harmful 
to patients ultimately compounds both clinical and societal 
value. 
 
Figure: Three-month moving average for mortality, TFPI 
(tifacogin) vs. placebo. From Abraham, E. et al. JAMA. 
2003;290:238-247. Used with permission. 
Recommendation 
Montori and coworkers have highlighted the potential 
problems associated with premature cessation of clinical 
trials. RCTs should only be stopped early when there is 
overwhelming evidence of benefit and after sufficient events 
have occurred. Just as clinical trial registry is now a 
requirement for publication, journals should also require 
adequate reporting about trial design and the decision to 
stop. 
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